Stage (next event)
Phase 1 (Results)
Catalyst Info & Data Links
TITLE: VK0214 for X-ALD phase 1 enrollment and IND submission
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
04-30-2020 IND Filing for VK0214 in X-ALD on Track for Mid Year (Q1 2020 Corporate Updated)
MECHANISM OF ACTION/ RATIONALE
VK0214 is a novel, orally available small molecule thyroid hormone receptor agonist that possesses selectivity for the beta receptor subtype. Data from an in vivo proof-of-concept study of VK0214 in X-ALD were presented at the 87th Annual Meeting of the American Thyroid Association, in Victoria, British Columbia. The results of this study demonstrated that long-term (25-week) treatment with VK0214 produced statistically significant reductions in plasma and tissue levels of very long chain fatty acids (VLCFAs) compared to vehicle-treated controls. VLCFA levels in central nervous system (CNS) tissues were also significantly reduced, suggesting a potential direct benefit in both brain and spinal cord. Treatment with VK0214 was also shown to stimulate significant increases in ABCD2 transporter expression in CNS tissue, providing further evidence of its effect beyond plasma exposures. These study results were consistent with the proposed mechanism of thyroid receptor beta (TRb)-mediated reductions in VLCFA levels, as ABCD2 is regulated by TRb and known to play a role in VLCFA metabolism. The successful outcome of this work serves to provide support for the role of selective TRb activation as a potential therapeutic approach to the disease (source)
Lenti-D - bluebird bio
MGTA-456 - Magenta Therapeutics
~1 in 17,000 newborns
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post